CN102755334A - Medicine composition of cycloartenyl ferulate - Google Patents
Medicine composition of cycloartenyl ferulate Download PDFInfo
- Publication number
- CN102755334A CN102755334A CN2012102708805A CN201210270880A CN102755334A CN 102755334 A CN102755334 A CN 102755334A CN 2012102708805 A CN2012102708805 A CN 2012102708805A CN 201210270880 A CN201210270880 A CN 201210270880A CN 102755334 A CN102755334 A CN 102755334A
- Authority
- CN
- China
- Prior art keywords
- cycloartenyl ferulate
- solution
- pharmaceutical composition
- injection
- gained
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a medicine composition of cycloartenyl ferulate. The medicine composition solves the problem that the cycloartenyl ferulate cannot dissolve in water easily and contains cycloartenyl ferulate and polyoxyl stearate. Stable and water-soluble oryzanol medicine composition solution is obtained by adding the cycloartenyl ferulate into the molten polyoxyl stearate. The invention further discloses a preparation method and preparation application of the medicine composition of cycloartenyl ferulate.
Description
The application is dividing an application of 201110004417.1 Chinese invention patent application for application number.
Technical field
The invention discloses a kind of pharmaceutical composition of cycloartenyl ferulate, comprise cycloartenyl ferulate and polyoxyl stearate, belong to field of medicaments.
Background technology
Oryzanol is a kind of natural mixture that the ferulic acid ester of the ferulic acid ester that is the main body with ring jackfruit alcohols and sterols is formed; Two kinds of main compositions are cycloartenyl ferulate and 24-methylene basic ring jackfruit alcohol ferulic acid ester; The content of the two is about about 70% in the oryzanol before the purification not, is the main active in the oryzanol.Discovery studies for a long period of time; Oryzanol has multiple pharmacologically active; Like the absorption of blood fat reducing, cholesterol reducing, prevent lipid oxidation, angiocardiopathy preventing, mitigation women various health obstacles and the vegetative dystonie phenomenon after entering into the climacteric period, improve the diencephalon functional disorder.
In existing technical scheme, adopt usually to add surfactants such as vegetable oil, phospholipid to oryzanol as injection, liposome, oral liquid etc.Injection oryzanol vegetable oil solubility preparation is all disclosed like Chinese patent CN123428, CN2007100156403 etc.; Thereby be oryzanol to be dissolved in the solution that has prepared oryzanol in the organic solvents such as soybean oil, ethyl oleate; But this type preparation only can be used for the preservation of oryzanol, can't directly apply to the human injection.If these oily solubility preparations are dissolved in water for injection or aqueous solution for injection, tangible profit two-phase layering can appear, the oryzanol deposition, so this type preparation does not have clinical value.One Chinese patent application CN200910211406 discloses a kind of microemulsion formulation of oryzanol, on traditional vegetable oil basis, adds solubilising adjuvants such as tween, glycerin, has prepared microemulsion.Although microemulsion formulation has improved the particle diameter under the oryzanol solution state, this scheme need be used a large amount of adjuvants on the one hand, and the gained drug quality is restive, is easy to generate impurity; It has still used macromolecular oils such as isopropyl myristate, Cortex cocois radicis wet goods on the other hand, and long-time stability are not good; 200710015604 disclose a kind of injection of oryzanol, use ethyl oleate as solubilizing agent, and the injection particle diameter of gained is very big, is easy to generate deposition; 99103000.1 disclose a kind of water miscible sitosterol compositions that comprises simple function surfactant and multifunctional surfactant, owing to need to use multiple molecules surfactant, its stability is not good.200410094556 disclose a kind of liposome of oryzanol, adopt phospholipid as adjuvant, have still that particle diameter is big, the problem of long-time stability difference.
Although above-mentioned disclosed technical scheme is obtaining some progress aspect the solution oryzanol water solublity; Therefore but effect is not fully up to expectations, and effect will be poorer aspect the poorer cycloartenyl ferulate of water solublity being used to solve can to expect these schemes.
Therefore still need a kind of indissoluble problem that can solve cycloartenyl ferulate, can have the technical scheme of stability preferably again.
Summary of the invention
In inventor's early-stage Study; Obtained cycloartenyl ferulate through effectively the component in the oryzanol being separated; The research is open in the patent 200810114405.2 of applicant's earlier application, and this full patent texts is introduced the reference as the application in full.Finding that to applicant in the research of the pure article of cycloartenyl ferulate its dissolubility in water is lower than oryzanol raw material; About 1/3 of oryzanol dissolubility is only arranged, and the technical scheme that traditional being used to solves the oryzanol solubilising all can't solve the problem that is insoluble in water of cycloartenyl ferulate.Through lot of experiments; The applicant is surprised to find that cycloartenyl ferulate joined and can accesses fully dissolving in the polyoxyl stearate under the molten condition, has excellent stability and fine solubility with adding the resulting cycloartenyl ferulate pharmaceutical composition of entry solution in this fused solution.Find based on this, the invention provides a kind of stable, significantly improved the deliquescent pharmaceutical composition of cycloartenyl ferulate, comprise cycloartenyl ferulate and polyoxyl stearate.The present invention also further provides and has contained the pharmaceutical preparation that above pharmaceutical composition and other pharmacy can be accepted adjuvant.Simultaneously, the present invention also provides above preparation of compositions method.
The invention discloses a kind of pharmaceutical composition of cycloartenyl ferulate, comprise cycloartenyl ferulate and polyoxyl stearate.In pharmaceutical composition of the present invention, the mass ratio of cycloartenyl ferulate and polyoxyl stearate is 1:5-200, is preferably 1:10-100, most preferably is 1:20-60.
Among the present invention; Cycloartenyl ferulate is not limited only to the method for separating and preparing of this chemical compound that the applicant provides in foregoing; Adopt technological means such as other chemosynthesis, separation and purification to obtain cycloartenyl ferulate, it still is applicable to solubilising scheme disclosed by the invention.Simultaneously as well known to those skilled in the art; Have difference through different separation methods or the resulting cycloartenyl ferulate purity of purifying technique, yet just can improve the dissolubility of cycloartenyl ferulate in water as long as use technical scheme of the present invention.
In the present invention, polyoxyl stearate is a kind of adjuvant of injection as emulsifying agent that pharmaceutically generally be used for, and is the polymer of polyethylene glycol mono stearate, and molecular formula is C
17H
35COO (CH
2CH
2O) nH, n representes different degree of polymerization, usually what pharmaceutically use n=2,6,8,10,12,20,25,30,32,40,50,60,100,150 etc. is arranged, and all can be applied to pharmaceutical composition of the present invention.The applicant finds through a large amount of experiments; Use the polyoxyl stearate of n=40 best for solubilising cycloartenyl ferulate effect; And consumption can be effectively controlled; Therefore preferably being applied to polyoxyl stearate of the present invention is polyoxyethylene stearate 40 esters (being called for short s40), i.e. n=40, and its fusing point is 46-51 ℃.Through cycloartenyl ferulate being dissolved in the polyoxyl stearate of molten state; Cycloartenyl ferulate disperses in the Molecular Geometries of polyoxyl stearate fully; Thereby by polyoxyl stearate institute enclose, solved the problem that cycloartenyl ferulate is insoluble in water.
Among the present invention, in order further to improve the stability of pharmaceutical composition, can add synergist, suitable synergist can be:
Poloxamer in polyoxyethylene-polyoxypropylene copolymer, preferred poloxamer 188;
Lecithin comprises egg yolk lecithin, soybean phospholipid, preferably soya lecithin;
Polyalcohols comprises organic polyhydric alcohol liquid under the room temperature, preferred propylene glycol, glycerin, ethylene glycol or its mixture;
Tweens, preferred polysorbate40, polysorbate60, Tween 80, most preferably Tween 80;
The basic amino acid acids comprises one or more the mixture in lysine, arginine, the histidine, preferred arginine;
Polyoxyethylene castor oil and derivant thereof (EL), especially polyoxyethylene hydrogenated Oleum Ricini (RH), preferred EL35, RH40.
Preferably, the synergist that is used for pharmaceutical composition of the present invention is tween, basic amino acid, polyoxyethylene castor oil, more preferably the mixture of one or more among Tween 80, arginine, the EL35.
When pharmaceutical composition of the present invention added above-mentioned synergist, the amount of its adding can be adjusted according to actual needs, and the 1/20-1 that preferably adopts the polyoxyl stearate quality doubly.
Test shows that pharmaceutical composition of the present invention has significantly improved the water solublity of cycloartenyl ferulate, and has good stability.The test that the while applicant carries out shows; Adding synergist not only can increase the stability of pharmaceutical composition of the present invention, and can further improve its water solublity: under equal consumption polyoxyl stearate, add synergist and can dissolve more cycloartenyl ferulate.
On the other hand, the present invention also provides said preparation of drug combination method, comprises polyoxyl stearate is heated to molten condition, and the step to wherein adding cycloartenyl ferulate further comprises the steps:
1. polyoxyl stearate is heated to fusion, stirs it is dissolved fully to wherein adding cycloartenyl ferulate.
2. the fused solution with step 1 joins in water or the aqueous solution, stirs to make its dissolving evenly.
In above-mentioned method for preparing step 1, to the polyoxyl stearate of different model different fusing points is arranged, therefore when heating, need adopt different heating temperature, this is conspicuous to those skilled in the art.
In above-mentioned method for preparing step 2, described aqueous solution can be the solution that has added pharmaceutic adjuvant commonly used, especially can be the aqueous solution that has added above-mentioned synergist.
On the basis of foregoing invention, pharmaceutical composition of the present invention can be prepared into different preparations and get into human body, normally oral liquid or injection, freeze-dried powder through suitable route of administration.Can adopt any adaptable formulation method that preparation of pharmaceutical compositions of the present invention is become pharmaceutical preparation.For example can the pharmaceutical composition solution of above-mentioned steps 2 gained be used the 0.45um membrane filtration, detect qualified after, the dress oral liquid bottle; Can the pharmaceutical composition solution of above-mentioned steps 2 gained be carried out technologies such as fine straining, dress cillin bottle through simple decarburization filtration sterilization, 0.22um microporous filter membrane and be prepared as injection; Can the pharmaceutical composition solution of above-mentioned steps 2 gained be added the suitable suitable freeze-dry process of employing such as lyophilizing proppant and be prepared into freeze-dried powder.To those skilled in the art, these preparation process are well-known.Same, according to different preparation needs, can add the common excipient substance in this area, also well known to a person skilled in the art, for example can add antioxidant, like EDTA, sodium metasulfite, sodium sulfite etc.; Fluidizer is like micropowder silica gel; The fragrance correctives is like saccharin sodium, Herba Menthae etc.
The applicant has carried out experiment proof pharmaceutical composition of the present invention to the dissolubility of pharmaceutical composition of the present invention with stability and has significantly improved the water solublity of cycloartenyl ferulate, and has good stable property.
The specific embodiment
Embodiment 1
Get 40g s6, under 60 ℃, be heated to molten condition, then to wherein adding the 8g cycloartenyl ferulate; Mix and stir 15min; With the gained fused solution join stir in the 5L water for injection to fully the dissolving, both pharmaceutical composition of the present invention, concentration is 1.6mg/ml.
Gained solution at room temperature leaves standstill clarification fully in 24 hours.
Embodiment 2
Get 100g s20, under 60 ℃, be heated to molten condition, then to wherein adding the 10g cycloartenyl ferulate; Mix and stir 30min; With the gained fused solution join stir in the 5L water for injection to fully the dissolving, both pharmaceutical composition of the present invention, concentration is 2mg/ml.
Gained solution at room temperature leaves standstill clarification fully in 24 hours.
Embodiment 3
Get 200g s40, under 70 ℃, be heated to molten condition, then to wherein adding the 5g cycloartenyl ferulate; Mix and stir 40min; With the gained fused solution join stir in the 4L water for injection to fully the dissolving, both pharmaceutical composition of the present invention, concentration is 1.25mg/ml.
Gained solution at room temperature leaves standstill clarification fully in 24 hours.
Embodiment 4
Get 400g s60, under 80 ℃, be heated to molten condition, then to wherein adding the 4g cycloartenyl ferulate; Mix and stir 30min; With the gained fused solution join stir in the 2L water for injection to fully the dissolving, both pharmaceutical composition of the present invention, concentration is 2mg/ml.
Gained solution at room temperature leaves standstill clarification fully in 24 hours.
Embodiment 5
Get 400g s100, under 90 ℃, be heated to molten condition, then to wherein adding the 2g cycloartenyl ferulate; Mix and stir 50min; With the gained fused solution join stir in the 2L water for injection to fully the dissolving, both pharmaceutical composition of the present invention, concentration is 1mg/ml.
Gained solution at room temperature leaves standstill clarification fully in 24 hours.
Embodiment 6
Get 120g s40; Under 70 ℃, be heated to molten condition; To wherein adding the 10g cycloartenyl ferulate, 30min is stirred in mixing then, the gained fused solution is joined stir in the 2L water for injection that has dissolved the 10g Tween 80 to dissolving fully; Both got pharmaceutical composition of the present invention, concentration is 5mg/ml.
Gained solution at room temperature leaves standstill clarification fully in 24 hours.
Embodiment 7
Get 150g s150; Under 90 ℃, be heated to molten condition; To wherein adding the 10g cycloartenyl ferulate, 30min is stirred in mixing then, the gained fused solution is joined stir in the 1L water for injection that has dissolved 30g EL35 to dissolving fully; Both got pharmaceutical composition of the present invention, concentration is 10mg/ml.
Gained solution at room temperature leaves standstill clarification fully in 24 hours.
Embodiment 8
Get 200g s40, under 60 ℃, be heated to molten condition, to wherein adding the 15g cycloartenyl ferulate, mix and stir 30min then, make its complete mix homogeneously to fused solution.Get the 10g arginine and be dissolved in the 1L water for injection, add fused solution behind the mixed dissolution fully, stir to dissolving fully, both got pharmaceutical composition of the present invention, concentration is 15mg/ml.
Gained solution at room temperature leaves standstill clarification fully in 24 hours.
Embodiment 9
Get 10g Tween 80 and 10g ethylene glycol, join in the 2L aqueous solution, stir to dissolving fully.
Get 100g s20, under 80 ℃, be heated to molten condition, then to wherein adding the 8g cycloartenyl ferulate; Mix and stir 20min; The gained fused solution is stirred to dissolving fully in above-mentioned Tween solution, both got pharmaceutical composition of the present invention, concentration is 4mg/ml.
Gained solution at room temperature leaves standstill clarification fully in 24 hours.
Embodiment 10
Get 10g lysine, 10g histidine, join mixing and stirring in the 2L water for injection.
Get 100g s60, under 90 ℃, be heated to molten condition, then to wherein adding the 10g cycloartenyl ferulate; Mix and stir 30min; With the gained fused solution join stir in the above-mentioned aqueous solution to fully the dissolving, both pharmaceutical composition of the present invention, concentration is 5mg/ml.
Gained solution at room temperature leaves standstill clarification fully in 24 hours.
Embodiment 11
Get 150g s40, under 70 ℃, be heated to molten condition, then to wherein adding the 10g cycloartenyl ferulate; Mix and stir 20min; With the gained fused solution join stir in the 2L water for injection to fully the dissolving, both pharmaceutical composition of the present invention, concentration is 5mg/ml.
Gained solution at room temperature leaves standstill clarification fully in 24 hours.
Embodiment 12
Get 120g s40, under 70 ℃, be heated to molten condition,, mix and stir 20min, get fused solution then to wherein adding the 15g cycloartenyl ferulate.Get the 5g arginine and join and stir in the 2L water for injection, add above-mentioned fused solution then and be stirred to fully dissolving to dissolving fully, both pharmaceutical composition of the present invention, concentration is 7.5mg/ml.
Gained solution at room temperature leaves standstill clarification fully in 24 hours.
On aforementioned pharmaceutical compositions solution basis, the technical method that it is prepared into pharmaceutical formulations such as injection, oral liquid is well-known to those skilled in the art.
For example can get the gained pharmaceutical composition solution of embodiment 1 gained and use the 0.45um membrane filtration, detect qualified after, the dress oral liquid bottle, both 800 of drug composition oral preparations of the present invention;
Can get embodiment 2 gained pharmaceutical composition solution and stir 30 minutes with 0.3% injection activated carbon, after decarburization was filtered, the dress cillin bottle had both got 1000 of medicine composition injections of the present invention after the 0.22um microporous filter membrane carried out fine straining;
The pharmaceutical composition solution that can get embodiment 3 adds 0.3% injection activated carbon and stirred 30 minutes, and decarburization after the 0.22um microporous filter membrane carries out fine straining, is adopted following freeze-dry process after filtering:
Pre-freeze: products temperature drops to-45 ℃, is incubated and promptly can carries out sublimation drying after 3 hours;
Sublimation drying: the sublimation drying temperature is controlled at below-12 ℃;
Dry again: the drying stage maximum temperature is controlled at 35 ℃ again, and loss on drying should be up to specification;
Behind dry the end, the intrinsic pressure plug of case, outlet lock aluminium lid, the qualified back of product inspection packing promptly gets 500 of lyophilized injection of pharmaceutical composition of the present invention.
The comparative example 1
Tween 80 40g
Poloxamer 188 40g
Maltose cyclodextrin 240g
Colloidal silica 22g
Starch 75g
Cycloartenyl ferulate 1120g
Water for injection 10L
Tween 80, poloxamer 188 are joined in the 1L water; Dissolve fully evenly to it 60 ℃ of following heated and stirred; Then to wherein adding remaining water; And adding starch, maltose cyclodextrin, colloidal silica, cycloartenyl ferulate, stirring makes its complete mix homogeneously both get injection.
The comparative example 2
The 2g cycloartenyl ferulate is joined in the 8g isopropyl myristate, is emulsifying agent with the 10g Tween 80, and the 10g glycerin is a cosolvent, be diluted with water to 1L be stirred to complete mix homogeneously both injection.
The comparative example 3
Get 100g s40, join in the 1L water to stir it is dissolved fully, to wherein adding the 5g cycloartenyl ferulate, mix and stir 30min then, be settled to 2L with water for injection, both injection.
Dissolving hardly, the room temperature held obvious sediment occurs after half an hour.
The comparative example 4
Get 200g PEG4000; Under 80 ℃, be heated to molten condition,, mix and stir 30min then to wherein adding the 5g cycloartenyl ferulate; With the gained fused solution join stir in the 2L water for injection to fully the dissolving, resulting composition concentration is 5mg/ml.
Gained solution at room temperature leaves standstill clarification basically after 24 hours.
The comparative example 5
Get 200g PVP K30; Under 80 ℃, be heated to molten condition,, mix and stir 30min then to wherein adding the 5g cycloartenyl ferulate; With the gained fused solution join stir in the 2L water for injection to fully the dissolving, resulting composition concentration is 5mg/ml.
Gained solution at room temperature leaves standstill and kept basic clarification in one hour, begins to occur muddy then.
The comparative example 6
Get 200g poloxamer 188; Under 80 ℃, be heated to molten condition,, mix and stir 30min then to wherein adding the 5g cycloartenyl ferulate; With the gained fused solution join stir in the 2L water for injection to fully the dissolving, resulting composition concentration is 5mg/ml.
Gained solution at room temperature leaves standstill after 24 hours the beginning muddiness has obvious sediment to separate out.
To above-mentioned sample, the applicant has carried out stability test, and is specific as follows:
Get the solution of embodiment 11,12 and comparative example 1,2,4 solution (being designated as sample number 1-5) and at room temperature preserved 1 year, detect its changes of contents, and write down its clarification situation, outcome record is in following table:
Table 1: long-time stability experimental result
Can know by above-mentioned data; Solubilising schemes such as Traditional use surfactant can't solve the indissoluble problem of the poorer cycloartenyl ferulate of water solublity; Adopt other fusion to be used for also poor effect of cycloartenyl ferulate solubilising with adjuvant, resulting ejection preparation all can't be realized stable the preservation; Technical scheme of the present invention then can provide the pharmaceutical composition solution of clarifying cycloartenyl ferulate steady in a long-term.
Simultaneously, the applicant gets the pharmaceutical composition solution of embodiment 11,12 and comparative example 1,2,4 injection (label is 1-5 respectively) has carried out the particle diameter test, and the gained result is as shown in table 2 below:
Table 2: particle diameter test result
| Sample | 1 | 2 | 3 | 4 | 5 |
| Particle diameter (nm) | 44.5 | 21.7 | 386 | 684 | 462 |
Can know that by above-mentioned data pharmaceutical composition solution of the present invention belongs to micellar scope, more near true solution. then particle diameter is very big for the solution of employing prior art scheme preparation, belongs to suspension or particle size of emulsion scope.Can find out also that thus the water-soluble problem that traditional scheme is used to solve cycloartenyl ferulate is infeasible.
Find out by table 1,2 data, on the basis of technical scheme of the present invention, add described synergist and can significantly improve the particle diameter of pharmaceutical composition solution of the present invention, and significantly improve its stability.
Claims (2)
1. a pharmaceutical composition comprises cycloartenyl ferulate and polyoxyl stearate.
2. according to the pharmaceutical composition of claim 1, the mass ratio of cycloartenyl ferulate and polyoxyl stearate is 1:5-200.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012102708805A CN102755334A (en) | 2011-01-11 | 2011-01-11 | Medicine composition of cycloartenyl ferulate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012102708805A CN102755334A (en) | 2011-01-11 | 2011-01-11 | Medicine composition of cycloartenyl ferulate |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110004417 Division CN102125566B (en) | 2011-01-11 | 2011-01-11 | Pharmaceutical composition comprising cycloartenyl ferulate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102755334A true CN102755334A (en) | 2012-10-31 |
Family
ID=47050151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012102708805A Pending CN102755334A (en) | 2011-01-11 | 2011-01-11 | Medicine composition of cycloartenyl ferulate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102755334A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103401861A (en) * | 2013-07-29 | 2013-11-20 | 深信服网络科技（深圳）有限公司 | Method and device of identifying proxy Internet |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102058538A (en) * | 2009-11-18 | 2011-05-18 | 北京世纪博康医药科技有限公司 | Cycloartenyl ferulate solid dispersion and preparation thereof |
-
2011
- 2011-01-11 CN CN2012102708805A patent/CN102755334A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102058538A (en) * | 2009-11-18 | 2011-05-18 | 北京世纪博康医药科技有限公司 | Cycloartenyl ferulate solid dispersion and preparation thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103401861A (en) * | 2013-07-29 | 2013-11-20 | 深信服网络科技（深圳）有限公司 | Method and device of identifying proxy Internet |
| CN103401861B (en) * | 2013-07-29 | 2016-08-10 | 深信服网络科技（深圳）有限公司 | Proxy surfing recognition methods and device |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101088524B (en) | Phosphatide composition of active skull cap components and prepn. process and prepn. thereof | |
| CN101926962B (en) | Hydroxypropyl-beta-cyclodextrin inclusion liposome of zedoary turmeric oil and preparation method thereof | |
| CN102686217B (en) | Submicro emulsion of paclitaxel using steroid complex as intermediate carrier | |
| KR102656823B1 (en) | An improved formulation of levosimendan for intravenous administration as an infusion or solution for injection and as a concentrate for infusion. | |
| CN100506208C (en) | Chansu-loaded nanoliposome and preparation method thereof | |
| CN110559682A (en) | Plant extract nanoparticle and preparation method and application thereof | |
| CN101088523B (en) | Nanometer solid lipid particle of active skullcap components and its prepn process and prepn | |
| CN104523606B (en) | The method that self-assembly method prepares gossypol and its derivative pluronic nano-particle | |
| CN105534904B (en) | Docetaxel for Injection composition and preparation method thereof | |
| CN102125565B (en) | Medicinal composition of 24-methylene cycloartenyl ferulate | |
| CN102058606B (en) | Oryzanol medicinal composition | |
| CN102755334A (en) | Medicine composition of cycloartenyl ferulate | |
| CN102125566B (en) | Pharmaceutical composition comprising cycloartenyl ferulate | |
| CN102451176A (en) | Docetaxel/steroid composite | |
| CN102058515B (en) | Solid dispersion of 24-methylene cycloartanol ferulic acid eater and preparation thereof | |
| CN101322719B (en) | Arsenic trioxide solid lipid nano granule and formulation | |
| JP2006509785A (en) | Oral microemulsion composition of biphenyldimethyldicarboxylic acid | |
| CN102038636B (en) | Taxane medicine solution containing chelating agent and preparation method thereof | |
| CN105663060B (en) | A kind of dianhydrogalactitol lipidosome freeze-dried injection and preparation method thereof | |
| CN102988484B (en) | Phosphatide complexes of Radix Scutellariae active skull cap components and preparation method thereof and preparation | |
| CN102188370A (en) | Resveratrol injection solution and intravenous injection | |
| CN102188369A (en) | Easily sublimating medicament injection solution and intravenous injection thereof | |
| CN107519187B (en) | Preparation method of fat-soluble vitamin freeze-dried milk | |
| CN103126992B (en) | Fat-soluble vitamin composite powder and preparation method thereof | |
| CN102133212B (en) | Asarone medical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20121031 |